TEM

Tempus AI Inc

Add to Watchlist

Advanced Chart

53.770

+0.870(+1.640%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

56.490

Open

53.960

VWAP

54.31

Vol

10.88M

Mkt Cap

9.30B

Low

52.170

Amount

591.07M

EV/EBITDA(TTM)

Total Shares

173.03M

9.14B

EV/OCF(TTM)

P/S(TTM)

11.06

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

9 Analyst Rating

16.48% Upside

Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 62.63 USD with a low forecast of 48.00 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

5 Hold

0 Sell

Moderate Buy

16.48% Upside

Current: 53.770

Low

48.00

Averages

62.63

High

74.00

16.48% Upside

Current: 53.770

Low

48.00

Averages

62.63

High

74.00

Needham

Ryan MacDonald

Strong Buy

Reiterates

$70

2025-04-24

New

Reason

Needham

Ryan MacDonald

Price Target

$70

2025-04-24

New

Reiterates

Strong Buy

Reason

BTIG

Mark Massaro

Strong Buy

Initiates

$60

2025-04-21

Reason

BTIG

Mark Massaro

Price Target

$60

2025-04-21

Initiates

Strong Buy

Reason

BTIG initiated coverage of Tempus AI with a Buy rating and $60 price target.

Needham

Ryan MacDonald

Strong Buy

Reiterates

$70

2025-04-10

Reason

Needham

Ryan MacDonald

Price Target

$70

2025-04-10

Reiterates

Strong Buy

Reason

Morgan Stanley

Tejas Savant

Buy

Maintains

$50 → $60

2025-03-06

Reason

Morgan Stanley

Tejas Savant

Price Target

$50 → $60

2025-03-06

Maintains

Buy

Reason

Piper Sandler

David Westenberg

Hold

Maintains

$70 → $55

2025-03-04

Reason

Piper Sandler

David Westenberg

Price Target

$70 → $55

2025-03-04

Maintains

Hold

Reason

Piper Sandler lowered the firm's price target on Tempus AI to $55 from $70 following quarterly results. The firm keeps a Neutral rating on the shares.

B of A Securities

Michael Ryskin

Hold

Maintains

$54 → $60

2025-03-03

Reason

B of A Securities

Michael Ryskin

Price Target

$54 → $60

2025-03-03

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tempus AI Inc (TEM.O) is -92.33, compared to its 5-year average forward P/E of -61.49. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-61.49

Current PE

-92.33

Overvalued PE

-32.07

Undervalued PE

-90.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

201.29

Current EV/EBITDA

1759.85

Overvalued EV/EBITDA

1023.32

Undervalued EV/EBITDA

-620.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.46

Current PS

7.40

Overvalued PS

10.29

Undervalued PS

6.64

Financials

Annual

Quarterly

FY2024Q4

YoY :

+35.85%

200.68M

Total Revenue

FY2024Q4

YoY :

+93.44%

-101.16M

Operating Profit

FY2024Q4

YoY :

-74.22%

-13.01M

Net Income after Tax

FY2024Q4

YoY :

-80.49%

-0.08

EPS - Diluted

FY2024Q4

YoY :

+9.86%

-47.21M

Free Cash Flow

FY2024Q4

YoY :

+10.20%

60.83

Gross Profit Margin - %

FY2024Q4

YoY :

-34.95%

-30.45

FCF Margin - %

FY2024Q4

YoY :

-81.04%

-6.48

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

49.1M

USD

3-6

Months

501.9M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

17.8M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

150.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

150.0K

Volume

Months

6-9

0.0

Volume

Months

0-12

17.4M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

75.0K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

49.1M

USD

3-6

Months

501.9M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

17.8M

USD

Months

0-12

0.0

USD

Months

TEM News & Events

Events Timeline

2025-04-23 (ET)

2025-04-23

13:37:08

BTIG says AstraZeneca deal demonstrates value of Tempus AI data AI business

2025-04-23

08:22:27

Tempus AI announces oncology collaboration with AstraZeneca, Pathos AI

2025-04-15 (ET)

2025-04-15

09:17:01

Illumina and Tempus AI partner for AI application in precision medicine

News

7.5

04-28TipRanks

Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM)

2.0

04-27Benzinga

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

1.0

04-25Newsfilter

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

People Also Watch

Midland States Bancorp Inc

Insteel Industries Inc

Financial Institutions Inc

Hingham Institution For Savings

Mind Medicine (MindMed) Inc

FAQ

What is Tempus AI Inc (TEM) stock price today?

The current price of TEM is 53.77 USD — it has increased 1.64 % in the last trading day.

TEM

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TEM News & Events

Events Timeline

News

People Also Watch

FAQ

What is Tempus AI Inc (TEM) stock price today?

What is Tempus AI Inc (TEM)'s business?

What is the price predicton of TEM Stock?

What is Tempus AI Inc (TEM)'s revenue for the last quarter?

What is Tempus AI Inc (TEM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Tempus AI Inc (TEM)'s fundamentals?

How many employees does Tempus AI Inc (TEM). have?

What is Tempus AI Inc (TEM) market cap?